{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:13:54Z","timestamp":1778901234858,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:13:12Z","timestamp":1746061992000},"page":"251-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials"],"prefix":"10.1016","volume":"9","author":[{"given":"Christopher J.D.","family":"Wallis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ekberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.03.001_b0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.03.001_b0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.001_b0015","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.001_b0020","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2967\/jnumed.119.240242","article-title":"Early prostate-specific antigen changes and clinical outcome after 177 Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer","volume":"61","author":"Gafita","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2025.03.001_b0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7150\/jca.7709","article-title":"Current approaches, challenges and future directions for monitoring treatment response in prostate cancer","volume":"5","author":"Wallace","year":"2014","journal-title":"J Cancer"},{"key":"10.1016\/j.euo.2025.03.001_b0030","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/cncr.31400","article-title":"Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy","volume":"124","author":"Bryant","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.03.001_b0035","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/pros.24754","article-title":"Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real\u2010world setting of metastatic hormone-sensitive prostate cancer patients","volume":"84","author":"Wenzel","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.03.001_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102140","article-title":"Clinical outcomes and risk stratification in patients with metastatic hormone-sensitive prostate cancer treated with new-generation androgen receptor signaling inhibitors","volume":"22","author":"Suzuki","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.03.001_b0045","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.001_b0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13104-021-05641-5","article-title":"Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer","volume":"14","author":"Nakanishi","year":"2021","journal-title":"BMC Res Notes"},{"issue":"16_suppl","key":"10.1016\/j.euo.2025.03.001_b0055","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1200\/JCO.2023.41.16_suppl.5070","article-title":"Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"41","author":"Halabi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.001_b0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/pros.24797","article-title":"Deep PSA response and extended timeA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitivrmone-sensitive prostate cancer receiving upfront intensified treatment","volume":"85","author":"Wong","year":"2025","journal-title":"Prostate"},{"issue":"4_suppl","key":"10.1016\/j.euo.2025.03.001_b0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2024.42.4_suppl.126","article-title":"Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): a secondary analysis of TITAN trial","volume":"42","author":"Roy","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.001_b0070","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.3390\/jcm13206221","article-title":"Ultralow prostate-specific antigen (PSA) levels and improved oncological outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with apalutamide: a real-world multicentre study","volume":"13","author":"L\u00f3pez-Abad","year":"2024","journal-title":"J Clin Med"},{"issue":"16_suppl","key":"10.1016\/j.euo.2025.03.001_b0075","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2023.41.16_suppl.5074","article-title":"Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216)","volume":"41","author":"Parikh","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.001_b0080","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2009.25.0654","article-title":"Basic concepts and methods for joint models of longitudinal and survival data","volume":"28","author":"Ibrahim","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.001_b0085","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/bcp.15200","article-title":"Modelling the association between biomarkers and clinical outcome: an introduction to nonlinear joint models","volume":"88","author":"Kerioui","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.euo.2025.03.001_b0090","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1208\/s12248-015-9745-5","article-title":"Nonlinear mixed-effect models for prostate-specific antigen kinetics and link with survival in the context of metastatic prostate cancer: a comparison by simulation of two-stage and joint approaches","volume":"17","author":"Desm\u00e9e","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.euo.2025.03.001_b0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.12426","article-title":"Comparison of joint and landmark modeling for predicting cancer progression in men with castration-resistant prostate cancer: a secondary post hoc analysis of the PREVAIL randomized clinical trial","volume":"4","author":"Finelli","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.03.001_b0100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1536867X20976311","article-title":"merlin\u2014A unified modeling framework for data analysis and methods development in Stata","volume":"20","author":"Crowther","year":"2020","journal-title":"Stata J Promot Commun Stat Stata"},{"key":"10.1016\/j.euo.2025.03.001_b0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12894-018-0353-4","article-title":"Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer","volume":"18","author":"Sato","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2025.03.001_b0110","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.3390\/cancers15174392","article-title":"Prognostic role of dynamic changes in serological markers in metastatic hormone na\u00efve prostate cancer","volume":"15","author":"Roy","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.03.001_b0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eururo.2007.08.041","article-title":"Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials","volume":"53","author":"Collette","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.001_b0120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41416-023-02190-5","article-title":"Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models","volume":"129","author":"Bruno","year":"2023","journal-title":"Br J Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:36:10Z","timestamp":1778898970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931125000537"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.03.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}